Blockchain Registration Transaction Record

Phio's Skin Cancer Therapy Shows 85% Response, Gains B2i Digital Spotlight

Phio Pharmaceuticals reports 85% response in Phase 1b skin cancer trial with PH-762, no serious adverse events. FDA submission targeted for 2026, cash extends to 2027. Selected as B2i Digital Featured Company.

This news matters because it highlights a significant advancement in cancer immunotherapy, specifically for difficult-to-treat skin cancers like cutaneous squamous cell carcinoma. The reported 65% overall pathological response rate and 85% response at the highest dose, coupled with no serious adverse events, suggest PH-762 could offer a safer, more effective treatment option compared to existing therapies. For patients, this represents hope for improved outcomes with fewer side effects. In the biotech investment landscape, Phio's strong safety profile, planned FDA engagement in 2026, and cash runway into 2027 position it as a compelling clinical-stage company, potentially attracting further investment and accelerating development. The broader impact includes advancing siRNA technology in oncology, which could pave the way for similar treatments in other cancers, benefiting both healthcare and biopharmaceutical innovation.